These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24612640)

  • 1. High HIV and HCV and the unmet needs of people who inject drugs in Yerevan, Armenia.
    Johnston L; Grigoryan S; Papoyan A; Grigoryan T; Balayan T; Zohrabyan L
    Int J Drug Policy; 2014 Jul; 25(4):740-3. PubMed ID: 24612640
    [No Abstract]   [Full Text] [Related]  

  • 2. People with Hepatitis C Who Inject Drugs - Underserved, Not Undeserving.
    Dore GJ; Trooskin S
    N Engl J Med; 2020 Aug; 383(7):608-611. PubMed ID: 32786185
    [No Abstract]   [Full Text] [Related]  

  • 3. High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey.
    Johnston L; Saumtally A; Corceal S; Mahadoo I; Oodally F
    Int J Drug Policy; 2011 Jul; 22(4):252-8. PubMed ID: 21700442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global epidemiology of hepatitis C virus infection.
    Shepard CW; Finelli L; Alter MJ
    Lancet Infect Dis; 2005 Sep; 5(9):558-67. PubMed ID: 16122679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of HIV and HCV infections among injection drug users in northeast India.
    Mahanta J; Borkakoty B; Das HK; Chelleng PK
    AIDS Care; 2009 Nov; 21(11):1420-4. PubMed ID: 20024719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meeting the challenge of injection drug use and HIV in Armenia.
    Markosyan KM; Kocharyan A; Potosyan A
    Health Hum Rights; 2006; 9(1):128-51. PubMed ID: 17061773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV and HCV infection among injecting drug users.
    Hagan H; Des Jarlais DC
    Mt Sinai J Med; 2000; 67(5-6):423-8. PubMed ID: 11064493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos AS; van der Helm JJ; Matser A; Prins M; Kretzschmar ME
    Addiction; 2013 Jun; 108(6):1070-81. PubMed ID: 23347124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia.
    Kikvidze T; Luhmann N; Avril E; Butsashvili M; Labartkava K; Etienne A; Le Pluart D; Inaridze I; Gamezardashvili A; Kharshiladze D; Bouscaillou J
    Int J Drug Policy; 2018 Feb; 52():16-19. PubMed ID: 29227878
    [No Abstract]   [Full Text] [Related]  

  • 10. Viral hepatitis and HIV infection among injection drug users in a central Iranian City.
    Sofian M; Aghakhani A; Banifazl M; Azadmanesh K; Farazi AA; McFarland W; Eslamifar A; Ramezani A
    J Addict Med; 2012 Dec; 6(4):292-6. PubMed ID: 22895463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological survey of hepatitis C virus infection in a cohort of patients from a ser.T in naples, Italy.
    Curcio F; Villano G; Masucci S; Plenzik M; Veneruso C; De Rosa G
    J Addict Med; 2011 Mar; 5(1):43-9. PubMed ID: 21769046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.
    Di Martino V; Rufat P; Boyer N; Renard P; Degos F; Martinot-Peignoux M; Matheron S; Le Moing V; Vachon F; Degott C; Valla D; Marcellin P
    Hepatology; 2001 Dec; 34(6):1193-9. PubMed ID: 11732009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes.
    Heinzerling KG; Kral AH; Flynn NM; Anderson RL; Scott A; Gilbert ML; Asch SM; Bluthenthal RN
    J Subst Abuse Treat; 2007 Jun; 32(4):423-9. PubMed ID: 17481466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV and HCV: distinct infections with important overlapping challenges.
    Wiktor S; Ford N; Ball A; Hirnschall G
    J Int AIDS Soc; 2014; 17(1):19323. PubMed ID: 25079438
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study.
    Judd A; Hickman M; Jones S; McDonald T; Parry JV; Stimson GV; Hall AJ
    BMJ; 2005 Jan; 330(7481):24-5. PubMed ID: 15533854
    [No Abstract]   [Full Text] [Related]  

  • 18. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
    Kemp R; Miller J; Lungley S; Baker M
    N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic hepatitis B and C in HIV-infected patients].
    Opravil M; Hunziker R; Lüthy R; Grob PJ
    Dtsch Med Wochenschr; 1998 Jun; 123(24):753-60. PubMed ID: 9672477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of late HIV diagnosis among people who inject drugs compared to men who have sex with men and heterosexual men and women in Australia.
    Wand H; Guy R; Law M; Wilson DP; Maher L
    AIDS Behav; 2013 Jan; 17(1):235-41. PubMed ID: 22218722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.